Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD

Pharmaceutical Development and Technology

Volumn 20, Issue 2, 2015, Pages 176-182

  Praschberger, Monika ^a   Cornelius, Carolin ^a   Schitegg, Markus ^a   Goldenberg, Hans ^a   Scheiber Mojdehkar, Barbara ^a   Sturm, Brigitte ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bioavailability; Biological stability; Generic intravenous iron; Iron sucrose; Iron uptake; Oxidative stress

Indexed keywords

CALCEIN; DICHLOROFLUORESCEIN; FERRITIN; IRON SACCHARATE; FERRIC ION; GENERIC DRUG; IRON(III)-HYDROXIDE SUCROSE COMPLEX; SUCROSE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; FLUORESCENT CALCEIN ASSAY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANEMIA, IRON-DEFICIENCY; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; DRUG RELEASE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL AVAILABILITY; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LIBERATION; DRUG STABILITY; DRUGS, GENERIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERRIC COMPOUNDS; FERRITINS; HEP G2 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MACROPHAGES; SPECTROPHOTOMETRY, ATOMIC; SUCROSE;

EID: 84922917617     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.852575     Document Type: Article

References (39)

1. Lee ES, Park BR, Kim JS, et al. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin 2013;29: 141-147
2. Madore F, White CT, Foley RN, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl. 2008;74:S7-S11
3. Gasche C, Evstatiev R, Haas T, et al. Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party. Z Gastroenterol Mai 2011;49:627-632
4. Breymann C, Bian X-M, Blanco-Capito LR, et al. Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med März 2011;39:113-121
5. Gomollón F, Gisbert JP. Intravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013;29:201-207
6. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 2013;7:9-22
7. Toblli J, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 2011;59:176-190
8. Rottembourg J, Kadri A, Leonard E, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011;26:3262-3267
9. Schellekens H, Klinger E, Mühlebach S, et al the therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011;59: 176-183
10. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 2012;11:66-78
11. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241-243
12. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010;25:3631-3640
13. Toblli JE, Cao G, Oliveri L. Differences between the original iron sucrose complex Venofer- and the iron sucrose similar Generis-, and potential implications. Port J Nephrol Hypert 2009;23:53-63
14. Bailie GR, Schuler C, Leggett RE, et al. Oxidative effect of several intravenous iron complexes in the rat. Biometals 2013;26:473-478
15. Martin-Malo A, Merino A, Carracedo J, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012;27:2465-2471
16. Meier T, Schropp P, Pater C, et al. Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittelforschung 2011;61:112-119
17. Elford P, Bouchard J, Jaillet L, et al. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. J Pharmacol Toxicol Methods 2013;68:374-383
18. Schaller G, Scheiber-Mojdehkar B, Wolzt M, et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 2005;68:2814-2822
19. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615-621
20. Fish WW. Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Meth Enzymol 1988;158: 357-364
21. Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 2003;270:3731-3738
22. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001;299: 194-202
23. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003;102:2670-2677
24. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990;186:1-85
25. Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 1992;42:703-710
26. Stäubli A, Boelsterli UA the labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am J Physiol Gastrointest Liver Physiol 1998;274: G1031-G1037
27. Breuer W, Greenberg E, Cabantchik ZI. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett 1997;403:213-219
28. Picard V, Renaudie F, Porcher C, et al. Overexpression of the ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution. Blood 1996;87:2057-2064
29. Lipiński P, Drapier J-C, Oliveira L, et al. Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H2O2. Blood 2000;95:2960-2966
30. Pierre JL, Fontecave M, Crichton RR. Chemistry for an essential biological process: the reduction of ferric iron. Biometals 2002;15: 341-346
31. Crichton R, Danielson B, Geisser P. Iron therapy with special emphasis on intravenous administration. Bremen (Germany): UNIMED; 2008:57-88
32. Sturm B, Laggner H, Ternes N, et al. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int 2005;67:1161-1170
33. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. 3rd ed. Oxford: Oxford Science Publications; 1999:191-198
34. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241-243
35. Scheiber-Mojdehkar B, Sturm B, Plank L, et al. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 2003;65:1973-1978
36. Ternes N, Scheiber-Mojdehkar B, Landgraf G, et al. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages. Nephrol Dial Transplant 2007;22:2824-2830
37. Sturm B, Steinkellner H, Ternes N, et al. In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. Arzneimittelforschung 2010;60:459-465
38. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012;89:87-93
39. Kakhlon O, Cabantchik ZI the labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 2002;33:1037-1046